Cargando…
Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies during the Omicron (B.1.1.529) Surge: Data from the Patient-Reported Leukemia & Lymphoma Society National Registry
Autores principales: | Reddy, Sneha T, Saltzman, Larry A, DeGennaro, Louis J, Nichols, Gwen L, Scott, Janaela, Senefeld, Jonathon W, Johnson, Patrick W, Greenberger, Lee M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665297/ http://dx.doi.org/10.1182/blood-2022-167321 |
Ejemplares similares
-
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021) -
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021) -
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021) -
Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry
por: Greenberger, Lee M, et al.
Publicado: (2021) -
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in
Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)